Blood filters in children with COVID-19 and acute kidney injury: A review.
Ther Apher Dial
; 26(3): 566-582, 2022 Jun.
Article
in English
| MEDLINE | ID: covidwho-1816498
ABSTRACT
COVID-19 has challenged the global healthcare system through rapid proliferation and lack of existing treatment resulting in over 180 million cases and 3.8 million deaths since December 2019. Although pediatric patients only comprise 1%-2% of diagnosed cases, their incidence of acute kidney injury ranges from 8.2% to 18.2% compared to 49% in adults. Severe infection, initiated by dysregulated host response, can lead to multiorgan failure. In this review, we focus on the use of various blood filters approved for use in pediatric kidney replacement therapy to mitigate adverse effects of severe illness. Therapeutic effects of these blood filters range from cytokine removal (CytoSorb, HA330, HCO/MCO), endotoxin removal (Toraymyxin, CPFA), both cytokine and endotoxin removal (oXiris), and nonspecific removal of proteins (PMMA) that have already been established and can be used to mitigate the various effects of the cytokine storm syndrome in COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Acute Kidney Injury
/
COVID-19
Type of study:
Observational study
Limits:
Adult
/
Child
/
Female
/
Humans
/
Male
Language:
English
Journal:
Ther Apher Dial
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
1744-9987.13793
Similar
MEDLINE
...
LILACS
LIS